Public company intelligence preview
IMPACT BIOMEDICAL INC
7 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $35675.00 average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 24 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Impact BioMedical Inc. is a Healthcare-sector, Biotechnology company built around discovering, patenting, and commercializing proprietary science for human healthcare and consumer wellness. Its portfolio includes Linebacker, Laetose, 3F, Equivir/Equivir G, and newer pathogen-mitigation products like Celios air purification, with monetization expected mainly through licensing, partnerships, and occasional direct sales. The business is still early-stage and IP-driven, with only modest product revenue and a heavy reliance on patent protection, regulatory progress, and partner adoption. Recent filings also highlight a small operating footprint, limited headcount, and continued concern about its ability to operate as a going concern.
Executive Compensation Practices
In a Biotechnology company like Impact BioMedical, executive compensation is typically shaped more by development milestones, licensing progress, capital formation, and patent expansion than by near-term sales growth. The filing summaries suggest compensation pressure from a low-revenue, high-burn environment, where management may use bonuses, equity awards, or retention incentives tied to commercialization of technologies such as Linebacker, Laetose, and Celios rather than traditional profitability metrics. The 2025 and 2024 disclosures also point to rising SG&A compensation, additional headcount, and bonus accruals, which can indicate management is rewarding execution of the business plan even while losses remain significant. For researchers, this means pay packages may be influenced by IPO-related scaling, partner negotiations, acquisition integration, and the need to retain a very small but specialized team.
Insider Trading Considerations
Insider trading activity in a small, IP-dependent Biotechnology company like Impact BioMedical may be especially sensitive to binary events such as licensing deals, patent outcomes, acquisition integration, financing transactions, and fair-value changes in related-party obligations. Because revenue is minimal and the company’s valuation can swing on commercialization milestones or capital raises, insiders may have strong incentives to buy or sell around news tied to the patent portfolio or the Celios and other product lines. The company’s going-concern language, ongoing need for financing, and reliance on related-party debt create additional context for interpreting trades, since insiders may act ahead of dilution, debt conversion, or equity issuance. Trading restrictions may also be more restrictive around patent announcements, merger discussions, and material partnership talks, which are especially important in the Biotechnology industry under the Healthcare sector.
Unlock the full IBO insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.